(PA12) Clinical Value of the Measurement of IFN-α and IFN-γ Producing Capacity using Whole Blood Method

Title Clinical Value of the Measurement of IFN-αand IFN-γ Producing Capacity using Whole Blood Method
Year 1995
Author K. Uno; K. Nakano; K. Kakimi; Y. Suginoshiya; H. Onodera; K. Akatani; N. Maruo; H. Mata; I. Kurosu; F Moriyasu; N. Ikegami; A. Kishi; T. Kishida
Publisher International Workshop on Nutritional Approach to Aging and Disease

CLINICAL VALUE OF THE MEASUREMENT OF IFN-α and IFN- γ PRODUCING CAPACITY USING WHOLE BLOOD METIIOD

K. Uno1, K. Nakano2, K. Kakimi3, Y. Suginoshiya3, H. Onodera2, K. Akatani1, N. Maruo1, H. Mata2, I. Kurosu4, F. Moriyasu3, N. lkegami5, A. Kishi1, T. Kishida1

1Kyoto Pasteur Inst., 2Kyoto Prefec., Univ. Med., 3Kyoto Univ. Dept. Med

4Nat. Hyogo Hospital, 5Nat. Osaka Hospital

IFN- α (induced by Sendai virus) and γ – (induced by PHA) producing capacities of healthy persons and patients with various diseases were measured using the whole blood method. IFN-α producing capacities of healthy men and women from 20-79 years of age were 8633 ± 3979 and 6885 ± 3811 IU/ml, respectively. Although the cause of disease states were variable, IFN-α producing capacities of patients with lung cancer ( 4321 ± 3876), myelodysplastic syndromes (913 ± 560), pulmonary tuberculosis (3090 ± 2765), non-insulin dependent diabetes mellitus (male: 6740±4901, female: 4885 ± 3824), hepatitis C (CIH:8045±5492 (male), 6506± 5621 (female), CAH:4880± 2772, LC:5100± 3525, HCC:4191 ± 2639) and asymptomatic HIV-1 carrier (3603 ± 2582 IU/ml) were all impaired. IFN-α producing capacities of patients with lung cancer or hepatitis C decreased gradually as the progression of the disease, while those of tuberculosis patients significantly increased after medication compared with values of just before hospitalization. Our research data on various diseases has demonstrated that IFN-α values are related to the subjects’ susceptibility to infection. Besides, measurement of IFN-α producing capacity is a unique in the sense that it stimulates in vivo-virus response in vitro by using the whole blood method.

The IFN- γ producing capacities of healthy men and women from 20-79 years of age were 37 ± 21 and 34±20 IU/ml, respectively. IFN- γ producing capacities decreased in patients during the terminal stages of lung cancer, while it increased in all stages of hepatitis C patients. As there are no correlation between PHA-induced lymphocyte proliferative responses which is attributed to whole T cell function and IFN- γ production which refers to Thl function, it is thought that both responses provide different aspects of immune functions.

The determination of IFN-α and γ producing capacity furnishes different aspects of immune functions which can’t be provided by conventional methods. Periodical measurement of IFN producing capacities might be helpful in determining patients’ immune status and would enable us to give suitable therapy at the appropriate time. We evaluated the effects of oral administration of dietary supplements such as Labre and Bio-normalizer on IFN producing capacity of human individuals by using this method.